Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker

Dermatology

Volumn 222, Issue 4, 2011, Pages 304-310

  Lee, Haur Yueh ^a   Pelivani, Nedzmidin ^a   Beltraminelli, Helmut ^a   Hegyi, Ivan ^a   Yawalkar, Nikhil ^a   Borradori, Luca ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Amicrobial pustulosis; Cutaneous lupus; Infliximab; Lupus erythematosus; Neutrophilic dermatoses; Tumor necrosis factor inhibitor

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; INFLIXIMAB; MYXOVIRUS RESISTANCE PROTEIN A; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AMICROBIAL PUSTULOSIS OF THE FOLDS; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; PUSTULOSIS; RASH; REVIEW; SKIN BIOPSY; SYMPTOM;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DERMATOLOGIC AGENTS; FEMALE; GASTROINTESTINAL AGENTS; GTP-BINDING PROTEINS; HUMANS; NEUTROPHILS; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80052491227     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000329428     Document Type: Review

References (38)

1. Crickx B: Pustulose amicrobienne et lupus érythémateux systémique. Journées Dermatologiques de Paris, Paris 1991, C11.
2. Kerl K, Masouyé I, Lesavre P, Saurat JH, Borradori L: A case of amicrobial pustulosis of the folds associated with neutrophilic gastrointestinal involvement with systemic lupus erythematosus. Dermatology 2005; 211: 356-359. (Pubitemid 41642112)
3. Antille C, Frei M, Sorg O, Tran C, Kaya G, Masouyé I, Fontao L, Prins C, Saurat JH: Amicrobial pustulosis of the folds associated with auto-immune disorders: A case report with an analysis of cytokine expression profile in skin lesions of cutaneous neutrophilic lupus. Dermatology 2008; 216: 324-329. (Pubitemid 351630098)
4. Lagrange S, Chowsidow O, Piette JC, Wechsler B, Godeau P, Frances C: A peculiar form of amicrobial pustulosis of the folds associated with systemic lupus erythematosus and other auto-immune diseases. Lupus 1997; 6: 514-520. (Pubitemid 27371219)
5. Marzano AV, Capsoni F, Berti E, Gasparini G, Bottelli S, Caputo R: Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: A new entity? Dermatology 1996; 193: 88-93. (Pubitemid 26297388)
6. Marzano AV, Ramoni S, Caputo R: Amicrobial pustulosis of the folds. Dermatology 2008; 216: 305-311.
7. Saiag P, Blanc F, Marinho E, De la Blanchardière A, Leconte I, Cocheton JJ, Tulliez M: Amicrobial pustulosis and systemic lupus erythematosus: A case. Ann Dermatol Venereol 1993; 120: 779-781. (Pubitemid 24019052)
8. Stefanidou MP, Kanavaros PE, Stefanaki KS, Tosca AD: Amicrobial pustulosis of the folds: A cutaneous manifestation associated with connective tissue disease. Dermatology 1998; 197: 394-396. (Pubitemid 29000799)
9. Kuyama M, Fujimoto W, Kambara H, Egusa M, Saitoh M, Yamasaki O, Maehara K, Ohara A, Arata J, Iwatsuki K: Amicrobial pustular dermatosis in two patients with immunological abnormalities. Clin Exp Dermatol 2002; 27: 286-289. (Pubitemid 34985124)
10. Lopez-Navarro, Alcaide A, Gallego E, Herrera- Acosta E, Gallardo M, Bosch RJ, Herrera E: Amicrobial pustulosis of the folds associated with Hashimoto's thyroiditis. Clin Exp Dermatol 2009; 34:e561-e563.
11. Lipsker D, Saurat JH: Neutrophilic cutaneous lupus erythematosus: At the edge between innate and acquired immunity? Dermatology 2008; 216: 283-286. (Pubitemid 351630092)
12. De Gannes G, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231. (Pubitemid 46294587)
13. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF: Histopathologic spectrum of psoriasiform skin reactions associated with tumour necrosis factor-alpha inhibitor therapy: A study of 16 biopsies. Am J Dermatol 2010; 32: 568-573.
14. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaverbeke T, Taieb A: Cytokine imbalance with increased production of interferonalpha in psoriasiform eruptions associated with anti-tumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161: 1081-1088.
15. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DPM: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology biologics register. Ann Rheum Dis 2009; 68: 209-215.
16. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ: Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol 2009; 61: 486-504.
17. Vazquez J, Almagro M, del Pozo J, Fonseca E: Neutrophilic pustulosis and ulcerative colitis. J Eur Acad Dermatol Venereol 2003; 17: 77-79. (Pubitemid 36163664)
18. Callen JP: Pustular eruptions in systemic diseases. Clin Dermatol 2000; 18: 349-353.
19. Sarkany R, Burrows NP, Grant JW, Pye RJ, Norris PG: The pustular eruption of ulcerative colitis. Br J Dermatol 1998; 138: 365-366.
20. Wenzel J, Tuting T: An IFN-associated cytotoxic cellular immune response against viral, self- or tumor antigens is a common pathogenic feature in 'interface dermatitis'. J Invest Dermatol 2008; 128: 2392-2402.
21. Kelly-Scumpia KM, Scumpia PO, Delano MJ, Weinstein JS, Cuenca AG, Wynn JL, Moldawer LL: Type 1 interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL 10. J Exp Med 2010; 207: 319-326.
22. Kerbleski JF, Gottlieb AB: Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58: 1033-1039.
23. Flendrie M, Vissers WHPM, Creemer MCW, de Jong Elke MGJ, van de Kerkhof PC, van Riel PLCM: Dermatological conditions during TNF-alpha blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Res Ther 2005; 7:R666-R676.
24. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert H, Audring H, Kary S, Burmester GR, Sterry W, Worm M: Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491.
25. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker M, Massaroti EM, Bush ML: Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor- alpha antagonists. J Am Acad 2009; 61: 104-111.
26. Fernandez-Torres R, Paradela S, Valbuena L, Fonseca E: Infliximab induced lichen planopilaris. Ann Pharmacother 2010; 44: 1501-1503.
27. Deng A, Harvey V, Sina B, Strobel D, Badros A, Jukins-Hopkins J, Samuels A, Oghilikhan M, Gaspari A: Interstitial granulomatous dermatitis associated with the use of tumour necrosis factor alpha inhibitors. Arch Dermatol 2006; 142: 198-202. (Pubitemid 43276531)
28. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA: Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 567-570. (Pubitemid 351498443)
29. Dhaille F, Viseux V, Caudron A, Dadban A, Tribout C, Bournier P, Clabaut A, Lok C: Cutaneous sarcoidosis occurring during anti- TNF-alpha treatment: Report of two cases. Dermatology 2010; 220: 234-237.
30. Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R: Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26: 2205-2206. (Pubitemid 350120373)
31. Williams EL, Gadola S, Edwards CJ: Anti- TNF-induced lupus. Rheumatology 2009; 48: 716-720.
32. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadradro MJ, Khamashta MA: Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine 2007; 86: 242-251. (Pubitemid 47067483)
33. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group: Autoimmune diseases induced by biological agents: A double- edged sword. Autoimmun Rev 2010; 9: 188-193.
34. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J: Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010; 146: 780-784.
35. Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, Morini JP, Gorin I, Ziza JM, Avril MF, Dupin N: Autoimmune bullous skin diseases occurring under antitumor necrosis factor therapy: Two case reports. Dermatology 2010; 221: 201-205.
36. Daulat S, Detweiler JG, Pandya AG: Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 2009; 23: 483-484.
37. Leombruno JP, Einarso TR, Keystone EC: The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-1145.
38. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D: Cancer risk with tumor necrosis factor alpha inhibitors: Metaanalysis of randomized controlled trials of adalimumab, etanercept and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-130.